8-K: Vivani Medical Secures $3 Million Equity Financing Amidst Promising Clinical Developments

Vivani Medical announces a $3 million equity financing and reports first quarter 2025 financial results, highlighting progress in its LIBERATE-1 study and preclinical data for NPM-139.

Summary

• Vivani Medical announced a $3 million equity financing and reported its first quarter 2025 financial results.
• The company's LIBERATE-1 study, evaluating the NPM-115 exenatide implant, is on track to deliver top-line data in mid-2025.
• All subjects in the NPM-115 cohort had successful insertions of the exenatide implant.
• Vivani also announced promising preclinical data for NPM-139, a semaglutide implant for chronic weight management.
• The company intends to spin off Cortigent, Inc., as an independent publicly traded company.
• Vivani's cash balance as of March 31, 2025, was $14.3 million.
• Research and development expenses for the quarter were $4.2 million.
• The net loss for the quarter was $6.3 million.
• The private placement is expected to close over two closing dates through March 15, 2026.

Sentiment

Score: 7

Explanation: The document presents a mix of positive developments (successful study enrollment, promising preclinical data, new financing) and negative aspects (net loss, cash decrease). The overall sentiment is cautiously optimistic, reflecting the company's progress in its clinical programs and financial stability, but also acknowledging the challenges and risks associated with drug development.

Positives

• Successful insertions of the exenatide implant in all subjects of the NPM-115 cohort in the LIBERATE-1 study.
• Promising preclinical data for NPM-139, indicating potential for chronic weight management.
• The $3 million equity financing, along with the previously reported $8.25 million, secures the company's financial position into mid-2026.
• The LIBERATE-1 study enrolled ahead of schedule.
• The company plans to spin off Cortigent, Inc., a division that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company.

Negatives

• The company reported a net loss of $6.3 million for the first quarter of 2025.
• Vivani's cash balance decreased by $5.4 million from December 31, 2024, to March 31, 2025.

Risks

• The company's future performance depends on the successful development and commercialization of its products, including NPM-115 and NPM-139.
• Delays in development, regulatory clearance, or clinical trials could negatively impact the company's prospects.
• Vivani has a history of losses and may need to access additional capital to fund its business.
• Market conditions and the ability of Cortigent to complete its initial public offering could affect the company's plans.

Future Outlook

Vivani anticipates top-line data from the LIBERATE-1 study in mid-2025 and plans to participate in the BIO International Convention in June 2025. The company aims to validate its NanoPortal implant technology and advance its portfolio of exenatide and semaglutide-based drug implants in clinical development.

Management Comments

• Vivani Chief Executive Officer Adam Mendelsohn, Ph.D., stated, 'Our ongoing first-in-human study, LIBERATE-1, remains on track to deliver key data in mid-2025 with the aim of validating our proprietary NanoPortal implant technology and enabling us to advance our portfolio of exenatide and semaglutide based drug implants in clinical development.'
• Dr. Mendelsohn added, 'While the GLP-1 market continues to grow and mature, it is clear that meaningful differentiation will be required for commercial success of new market entrants, in part because of the significant clinical benefits delivered by the currently available GLP-1 therapies.'
• Dr. Mendelsohn stated, 'We remain confident that our emerging portfolio of convenient, miniature, subdermal drug implants with onceor twice-yearly dosing will stand out as a highly differentiated and sought-after alternative GLP-1 treatment option for patients and providers, with the potential to substantially improve patient outcomes by addressing poor medication adherence and patient tolerability.'

Industry Context

Vivani Medical is operating in the growing GLP-1 market, focusing on developing differentiated drug implants for chronic weight management and type 2 diabetes. The company aims to address medication adherence challenges with its long-acting implant technology, positioning itself as a potential alternative to daily or weekly orals and injectables.

Comparison to Industry Standards

• The document mentions that the liver fat reduction results in obese mice are numerically consistent with a similar investigation in which liver fat content was evaluated in high fat diet-induced obese mice that received semaglutide injections.
• The company believes that its emerging portfolio of convenient, miniature, subdermal drug implants with onceor twice-yearly dosing will stand out as a highly differentiated and sought-after alternative GLP-1 treatment option for patients and providers, with the potential to substantially improve patient outcomes by addressing poor medication adherence and patient tolerability.

Related Party Transactions

• Vivani Medical, Inc. (the Company) entered into a Share Purchase Agreement, effective May 12, 2025, with an entity beneficially owned by Gregg Williams, Chairman of the Board of Directors of the Company (the Purchaser) for the purchase of an aggregate of 2,912,621 shares of common stock of the Company priced at $1.03 per share (the Shares).

Stakeholder Impact

• Shareholders: The equity financing and clinical progress could positively impact shareholder value.
• Employees: The spin-off of Cortigent could create new opportunities for employees in both companies.
• Patients: Successful development of the drug implants could provide a more convenient and effective treatment option for chronic weight management and type 2 diabetes.
• Strategic Partners: The company is actively seeking strategic partners to advance its programs.

Next Steps

• Vivani anticipates top-line data from the LIBERATE-1 study in mid-2025.
• Vivani plans to participate in the BIO International Convention in Boston, MA from June 16 to 19, 2025.
• The company intends to spin off Cortigent, Inc., as an independent publicly traded company.

Key Dates

Keywords

Vivani Medical, equity financing, LIBERATE-1, NPM-115, NPM-139, Cortigent, exenatide, semaglutide, GLP-1, weight management, diabetes, NanoPortal, implant technology, clinical trial, biopharmaceutical